Cart
sales@molnova.com
SKLB 1028
CAS No. 1350544-93-2
SKLB 1028( —— )
Catalog No. M34711 CAS No. 1350544-93-2
SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 139 | In Stock |
|
| 5MG | 116 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 377 | In Stock |
|
| 50MG | 548 | In Stock |
|
| 100MG | 784 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1609 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSKLB 1028
-
NoteResearch use only, not for human use.
-
Brief DescriptionSKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants.
-
DescriptionRuserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity.
-
In Vitro——
-
In VivoAnimal Model:MV4-11 and K562 xenograft NOD-SCID modelsDosage:5, 10, 20 mg/kg,70 mg/kg Administration:orally once daily, 18 days Result:Prevented tumor growth at a dose of 5 mg/kg, and caused rapid and complete tumor regression in both groups of mice at a dose of 10 or 20 mg/kg.Significantly inhibited the proliferation and induced apoptosis of MV4-11 and K562 cells at a dose of 70 mg/kg.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR | FLT | Bcr-Abl
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1350544-93-2
-
Formula Weight443.55
-
Molecular FormulaC24H29N9
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (563.63 mM; Ultrasonic )
-
SMILESC(C)(C)N1C=2C(N=C1NC=3C=CC=NC3)=CN=C(NC4=CC=C(C=C4)N5CCN(C)CC5)N2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Z-X Cao, et al. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants. Leukemia. 2012 Aug;26(8):1892-5.?
molnova catalog
related products
-
FRAX597
FRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM).
-
Tiotropium Bromide h...
Tiotropium Bromide hydrate is a monohydrate of tiotropium bromide (Spiriva; Tiova; BA 679BR; tiopropium) that is an anticholinergic and bronchodilator and a muscarinic receptor antagonist.
-
Almonertinib mesylat...
Almonertinib mesylate is an irreversible inhibitor of EGFR tyrosine kinase with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate can be used in the non-small cell lung cancer studies.
